Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen meets Street EPS

AMGN reported first quarter EPS of $0.25 after the market close

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE